Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy
Latest Information Update: 13 Jul 2013
At a glance
- Drugs CYT 005 AllQbG10 (Primary) ; House dust mite allergy immunotherapy; Vidutolimod
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Cytos Biotechnology
- 19 Feb 2008 The expected completion date for this trial is now 1 Mar 2008.
- 14 Jun 2006 New trial record.